Feng-Cai Zhu

1. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
   2020/05/22 by Feng-Cai Zhu, Fengcai Zhu, Yu-Hua Li +23 · 6 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #COVID-19 Clinical Research Studies #SARS-CoV-2 and COVID-19 Research #Virus-based gene therapy research
2. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
   2020/07/20 by Fengcai Zhu, Feng-Cai Zhu, Xu-Hua Guan +32 · 3 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #COVID-19 Clinical Research Studies #SARS-CoV-2 and COVID-19 Research #Virus-based gene therapy research